Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

Video

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Lucy Gilbert, MD, MSc, professor, ​Department​s of ​Obstetrics ​and Gynecology, and Oncology, McGill University​, director, Gynecologic Oncology and Women’s Health Research Unit, McGill University Health Center, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab (Avastin) in patients with platinum-agnostic ovarian cancer.

Upon recurrence, patients with ovarian cancer are defined as platinum-sensitive or platinum-resistant, Gilbert explains. Single-agent mirvetuximab soravtansine demonstrated effectiveness in platinum-resistant patients.

Patients with platinum-sensitive disease are eligible to receive platinum chemotherapy; however, response rates are low with platinum alone, says Gilbert.

As such, utilizing the combination of mirvetuximab soravtansine and bevacizumab may be effective in patients with ovarian cancer who are eligible for a non-platinum–based doublet, concludes Gilbert.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD